Regorafenib (Stivarga®) is indicated for the treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies. These include fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy.
|12/09/2013||02/10/2013||Full Pharmacoeconomic Evaluation Recommended|
|14/02/2014||30/06/2014||Reimbursement Not Recommended|
The NCPE does not recommend regorafenib (Stivarga®) as a cost-effective treatment option.
Following discussions between the HSE and the company, regorafenib is now reimbursed under a patient access scheme.